Arboris enters US market with flagship plant sterol ester

- Last updated on GMT

Daily consumption of 1.5 to 3 grams of phytosterols/-stanols from foods may reduce total cholesterol levels by 8-17%
Daily consumption of 1.5 to 3 grams of phytosterols/-stanols from foods may reduce total cholesterol levels by 8-17%
Georgia-based Arboris, LLC has launched its pine-derived plant sterol ester ingredient Protanica into North American markets.

The ingredient is said to be compatible with both organic and non-GMO certified foods, and suitable for a wide range of applications, including dairy beverages, cookies, yogurts, smoothies and others will include heart healthy sterols in their offerings.

Phytosterols and stanols are the cholesterol-reduction market’s established leaders, with clinical data indicating that daily consumption of 1.5 to 3 grams of phytosterols/-stanols from foods can reduce total cholesterol levels by 8-17%.

The European Atherosclerosis Society (EAS) recently published a ‘Consensus Statement’ stating: "Two grams of plant sterols or plant stanols per day in functional foods can help manage cholesterol for those with moderate heart disease risk and who are taking statin drugs." 

Manuel Canales, President and CEO, Arboris, LLC, said: “Well understood and accepted in other parts of the world, the US is beginning to recognize the health benefits of plant sterol esters as a functional ingredient for heart healthy foods.​  

“We are seeing an increased interest among food manufactures looking to increase the heart-healthy cholesterol-lowering properties of their products.  Protanica is a supported product offered to food manufacturers and retailers to help the formulation and launch of such products.”

High cholesterol levels, hypercholesterolemia, have a long association with many diseases, particularly cardiovascular disease (CVD), the cause of almost 50 per cent of deaths in Europe and the US.

A report from the American Heart Association predicted a tripling of direct medical costs of cardiovascular disease from $272.5 billion to $818.1 billion between 2010 and 2030 (Circulation​, March 2011, Vol. 123, pp. 933-944).

Related topics: Suppliers, Cardiovascular health

Related news

Related products

show more

Resveratrol – Revitalizing Cognitive Function

Resveratrol – Revitalizing Cognitive Function

Evolva | 29-Sep-2017 | Technical / White Paper

Cognitive decline is fast becoming the biggest concern of the 65+ population. A population which is set to reach 1.1 billion by 2030*.  · 80% of 60+ take...

Product Cost Reduction Strategies for the Brand Owner

Product Cost Reduction Strategies for the Brand Owner

Gemini Pharmaceuticals | 11-Sep-2017 | Technical / White Paper

Brand Owners are feeling product price pressure from all corners these days. Consumers are demanding more of the products they buy and want them at a lower...

NattoPharma

12 Reasons MenaQ7® is the Superior Vitamin K2

NattoPharma USA, Inc. | 11-Sep-2017 | Data Sheet

Vitamin K2 as MK-7 supplements are truly changing the face of global health, benefiting old and young alike. We know this because NattoPharma has single-handedly...

Related suppliers

Follow us

Products

View more

Webinars